Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Culprits

<< Previous

Bullboard Posts

Next >>

Comment by robertshawon Nov 30, 2021 12:14pm

475 Views

Post# 34180653

RE:Culprits

langosta wrote:

Year Company Settlement Violation(s) Product(s) Laws allegedly violated
(if applicable)

2012 GlaxoSmithKline^[1]^[6] $3 billion ($1B criminal, $2B civil) Criminal: Off-label promotion, failure to disclose safety data.
Civil: paying kickbacks to physicians, making false and misleading statements concerning the safety of Avandia, reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program Avandia (not providing safety data), Wellbutrin, Paxil (promotion of paediatric use), Advair, Lamictal, Zofran, Imitrex, Lotronex, Flovent, Valtrex False Claims Act, FDCA

2009 Pfizer^[2] $2.3 billion Off-label promotion, kickbacks Bextra, Geodon, Zyvox, Lyrica False Claims Act, FDCA

2013 Johnson & Johnson^[7] $2.2 billion Off-label promotion, kickbacks Risperdal, Invega, Nesiritide False Claims Act, FDCA

2012 Abbott Laboratories^[8] $1.5 billion Off-label promotion Depakote False Claims Act, FDCA

2009 Eli Lilly^[9] $1.4 billion Off-label promotion Zyprexa False Claims Act, FDCA

2001 TAP Pharmaceutical Products^[10] $875 million Medicare fraud, kickbacks Lupron False Claims Act, Prescription Drug Marketing Act

2012 Amgen^[11] $762 million Off-label promotion, kickbacks Aranesp False Claims Act, FDCA

2010 GlaxoSmithKline^[12] $750 million Poor manufacturing practices Kytril, Bactroban, Paxil CR, Avandamet False Claims Act, FDCA

2005 Serono^[13] $704 million Off-label promotion, kickbacks, monopolistic practices Serostim False Claims Act

2008 Merck^[14] $650 million Medicare fraud, kickbacks Zocor, Vioxx, Pepsid False Claims Act, Medicaid Rebate Statute

2007 Purdue Pharma^[15] $601 million Off-label promotion Oxycontin False Claims Act

2010 Allergan^[16] $600 million Off-label promotion Botox False Claims Act, FDCA

2010 AstraZeneca^[17] $520 million Off-label promotion, kickbacks Seroquel False Claims Act

2007 Bristol-Myers Squibb^[18] $515 million Off-label promotion, kickbacks, Medicare fraud Abilify, Serzone False Claims Act, FDCA

Year	Company	Settlement	Violation(s)	Product(s)	Laws allegedly violated (if applicable)
2012	GlaxoSmithKline^[1]^[6]	$3 billion ($1B criminal, $2B civil)	Criminal: Off-label promotion, failure to disclose safety data. Civil: paying kickbacks to physicians, making false and misleading statements concerning the safety of Avandia, reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program	Avandia (not providing safety data), Wellbutrin, Paxil (promotion of paediatric use), Advair, Lamictal, Zofran, Imitrex, Lotronex, Flovent, Valtrex	False Claims Act, FDCA
2009	Pfizer^[2]	$2.3 billion	Off-label promotion, kickbacks	Bextra, Geodon, Zyvox, Lyrica	False Claims Act, FDCA
2013	Johnson & Johnson^[7]	$2.2 billion	Off-label promotion, kickbacks	Risperdal, Invega, Nesiritide	False Claims Act, FDCA
2012	Abbott Laboratories^[8]	$1.5 billion	Off-label promotion	Depakote	False Claims Act, FDCA
2009	Eli Lilly^[9]	$1.4 billion	Off-label promotion	Zyprexa	False Claims Act, FDCA
2001	TAP Pharmaceutical Products^[10]	$875 million	Medicare fraud, kickbacks	Lupron	False Claims Act, Prescription Drug Marketing Act
2012	Amgen^[11]	$762 million	Off-label promotion, kickbacks	Aranesp	False Claims Act, FDCA
2010	GlaxoSmithKline^[12]	$750 million	Poor manufacturing practices	Kytril, Bactroban, Paxil CR, Avandamet	False Claims Act, FDCA
2005	Serono^[13]	$704 million	Off-label promotion, kickbacks, monopolistic practices	Serostim	False Claims Act
2008	Merck^[14]	$650 million	Medicare fraud, kickbacks	Zocor, Vioxx, Pepsid	False Claims Act, Medicaid Rebate Statute
2007	Purdue Pharma^[15]	$601 million	Off-label promotion	Oxycontin	False Claims Act
2010	Allergan^[16]	$600 million	Off-label promotion	Botox	False Claims Act, FDCA
2010	AstraZeneca^[17]	$520 million	Off-label promotion, kickbacks	Seroquel	False Claims Act
2007	Bristol-Myers Squibb^[18]	$515 million	Off-label promotion, kickbacks, Medicare fraud	Abilify, Serzone	False Claims Act, FDCA